MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.14% | 36.37% | 46.28% | 19.27% | 26.62% |
| Total Depreciation and Amortization | -35.64% | -34.53% | -22.85% | 1.95% | 16.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.50% | -46.07% | 133.35% | 130.29% | 157.53% |
| Change in Net Operating Assets | -120.28% | -129.18% | -162.38% | -52.65% | -7.69% |
| Cash from Operations | -191.46% | -47.24% | 43.94% | 61.32% | 83.57% |
| Capital Expenditure | 38.94% | 65.87% | 63.73% | 67.94% | 65.66% |
| Sale of Property, Plant, and Equipment | 519.31% | 55.75% | -99.22% | -72.88% | -61.16% |
| Cash Acquisitions | -- | -- | -- | -- | -100.00% |
| Divestitures | -- | -- | -- | -- | -29.51% |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -5.58% | -37.90% | -102.01% | -93.93% | -42.65% |
| Total Debt Issued | -37.42% | -26.57% | -25.12% | -25.12% | -25.12% |
| Total Debt Repaid | 74.04% | -147.96% | -63.38% | -51.72% | -43.88% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.90% | -64.97% | -80.98% | -32.12% | -18.23% |
| Cash from Financing | 96.32% | -3,250.97% | -498.90% | -405.53% | -252.49% |
| Foreign Exchange rate Adjustments | 100.18% | 106.52% | 102.60% | 101.58% | -73.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,709.47% | -546.65% | -148.24% | 0.53% | 102.19% |